Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
Related Presenters
Associate Director, Clinical Research
Dr. Waks received her undergraduate degree from Princeton University in 2006 and her MD degree from Harvard Medical School in 2011. She completed residency training in internal medicine at Brigham and Women's Hospital, where she subsequently ...
